Table 3.

Participant details of participants included in the clustering analyses

	Autism		Control
	Cluster 1 N = 83	Cluster 2 N = 36	Cluster 3 N = 66	Cluster 4 N = 24
Age	16.62 ± 5.69 7.47–29.57	15.45 ± 6.52 6.23–28.74	16.72 ± 6.23 7.55–29.84	14.44 ± 4.82 7.68–27.11
VIQ	109.22 ± 16.13 66–160	85.6 ± 17.38 45–121	113.81 ± 13.98 89–160	96.25 ± 25.66 51–138
PIQ	109.27 ± 15.15 75–148	88 ± 20.27 53–132	111.77 ± 13.25 85–136	93.67 ± 25.9 49–139
ADOS	4.69 ± 2.43 1–9	6.84 ± 2.54 2–10	N/A	N/A
SRS	69.33 ± 12.7 44–90	77.33 ± 10.46 53–90	44.31 ± 5.69 37–66	51.68 ± 12.75 38–76
RBS	14.22 ± 12.87 0–54	24.03 ± 15.46 1–60	1.06 ± 2.49 0–12	3.42 ± 5.36 0–17
VABS-2	78.75 ± 15.43 20–110	66.82 ± 20.25 20–115	123.5 ± 9.69 117–141	51.25 ± 31.6 28–96
Sex m:f	51:32	29:7	40:26	20:4
ID participants	1 (1.2%)	10 (27.7%)	0 (0%)	8 (33.3%)
Neuropsychiatric symptoms*	29 (34.9%)	17 (47.2%)	0 (0%)	3 (12.5%)
ID + Neuropsychiatric symptoms*	0 (0%)	5 (13.9%)	0 (0%)	3 (12.5%)
Medication use	39	18	11	6